| International multisite double-blind trial of the atypical antipsychotics risperidone and olanzapine in 175 elderly patients with chronic schizophrenia. | |
| | |
MedLine Citation:
|
PMID: 14609804 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: The authors compared the effects of the two most commonly used atypical antipsychotics, risperidone and olanzapine, in elderly patients with schizophrenia. METHODS: In an 8-week, international, double-blind study, patients (outpatients, hospital inpatients, and residents of nursing or boarding homes) were randomly assigned to receive risperidone (1 mg to 3 mg/day) or olanzapine (5 mg to 20 mg/day). The main outcome measures were changes in Positive and Negative Syndrome Scale (PANSS) total scores and rates of extrapyramidal symptoms (EPS). RESULTS: Subjects were 175 patients age 60 years or over with schizophrenia or schizoaffective disorder. The mean duration of illness was 36.5 years. Median doses were 2 mg/day of risperidone and 10 mg/day of olanzapine. PANSS total scores and four of the five PANSS factor scores (positive symptoms, negative symptoms, disorganized thoughts, and anxiety/depression) improved significantly at all time-points and at endpoint in both groups; between-treatment differences were not significant. EPS-related adverse events were reported by 9.2% of patients in the risperidone group and 15.9% in the olanzapine group; the between-treatment difference was not significant. Total scores on the Extrapyramidal Symptom Rating Scale were reduced in both groups at endpoint; between-treatment differences were not significant. Clinically relevant weight gain was seen in both groups, but was significantly less frequent in risperidone patients than in olanzapine patients. CONCLUSIONS: Stable elderly patients with chronic schizophrenia receiving appropriate doses of risperidone or olanzapine over an 8-week period experienced significant reductions in the severity of psychotic and extrapyramidal symptoms, with a relatively low risk of side effects. |
| | |
Authors:
|
Dilip V Jeste; Yoram Barak; Subramoniam Madhusoodanan; Fred Grossman; Georges Gharabawi |
Related Documents
:
|
15641874 - Weight gain during treatment of bipolar i patients with olanzapine. 21095214 - Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophre... 11838824 - A study of quetiapine: efficacy and tolerability in psychotic adolescents. 20216424 - Medication satisfaction in schizophrenia: a blinded-initiation study of paliperidone ex... 21553144 - Evaluating patient adherence to antidepressant therapy among uninsured working adults d... 23660224 - Development and validation of the chinese overactive bladder symptom score for assessin... |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry Volume: 11 ISSN: 1064-7481 ISO Abbreviation: Am J Geriatr Psychiatry Publication Date: 2003 Nov-Dec |
Date Detail:
|
Created Date: 2003-11-11 Completed Date: 2004-03-12 Revised Date: 2008-11-21 |
Medline Journal Info:
|
Nlm Unique ID: 9309609 Medline TA: Am J Geriatr Psychiatry Country: United States |
Other Details:
|
Languages: eng Pagination: 638-47 Citation Subset: IM |
Affiliation:
|
University of California, San Diego, CA 92161, USA. djeste@ucsd.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Antipsychotic Agents / administration & dosage, therapeutic use* Benzodiazepines / therapeutic use* Chronic Disease Diagnostic and Statistical Manual of Mental Disorders Double-Blind Method Drug Administration Schedule Female Humans Male Risperidone / administration & dosage, therapeutic use* Schizophrenia / diagnosis, drug therapy* Severity of Illness Index |
| Chemical | |
Reg. No./Substance:
|
0/Antipsychotic Agents; 106266-06-2/Risperidone; 12794-10-4/Benzodiazepines; 132539-06-1/olanzapine |
| Comments/Corrections | |
Erratum In:
|
Am J Geriatr Psychiatry. 2004 Jan-Feb;12(1):49 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Functioning and well-being of middle-aged and older patients with schizophrenia: measurement with th...
Next Document: Medicare and medicaid costs for schizophrenia patients by age cohort compared with costs for depress...